Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746327 | 0.87 | NR4A2 (0.48) | NR4A2GAAL3MBTL1ALDH1A1SLC6A3 | |
| SCHEMBL27726722 | 0.87 | NR4A2 (0.48) | NR4A2GAAL3MBTL1ALDH1A1SLC6A3 | |
| SCHEMBL16959542 | 0.83 | NR4A2 (0.48) | NR4A2GAAL3MBTL1ALDH1A1SLC6A3 | |
| SCHEMBL26732932 | 0.83 | NR4A2 (0.48) | NR4A2GAAL3MBTL1ALDH1A1SLC6A3 | |
| SCHEMBL4598114 | 0.81 | KDM4E (0.57) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15779058 | 0.81 | GAA (0.51) | NR4A2GAAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL257348 | 0.80 | GAA (0.47) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16049537 | 0.80 | GAA (0.60) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16961730 | 0.80 | GAA (0.47) | GAAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17197313 | 0.80 | CYP1A2 (0.56) | NR4A2GAAALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4663626-A1 | IMINE COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Bio Genuine (Shanghai) Biotech Co., Ltd (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| CN-102239152-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2011-11-09 | — | — | CN | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
| CN-101341145-A | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | NR4A2 1906/4885GAA 1175/4885L3MBTL1 1152/4885 |
| US-20260146050-A1 | KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES | KRAS, NRAS, HRAS | NR4A2 921/4885GAA 1402/4885L3MBTL1 2998/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | NR4A2 134/4885GAA 2258/4885L3MBTL1 1536/4885 |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | NR4A2 4047/4885GAA 1882/4885L3MBTL1 3648/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | NR4A2 1906/4885GAA 1175/4885L3MBTL1 1152/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | NR4A2 134/4885GAA 2258/4885L3MBTL1 1536/4885 |
| US-20240325547-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | NR4A2 2214/4885GAA 1828/4885L3MBTL1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.